Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.AZRX · Entity 7534 | Director | April 06, 2020 | April 07, 2020 |
| Perspective Therapeutics, Inc.CATX · Entity 694 | Director · Chief Executive Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date April 06, 2020 · Filed April 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2030-04-06 | Direct | 80,000 |
Reported balance
After 2020-04-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-06 · Grant · Acquired 80,000 · Balance 80,000 F2: Options issued in connection with the Reporting Person's service on the Issuer's Board of Directors. F1: 25% of the options vest immediately, with the remainder vesting in equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options vest immediately, with the remainder vesting in equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020.
F2: Options issued in connection with the Reporting Person's service on the Issuer's Board of Directors.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 735,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 735,000 · Balance 735,000 F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.
F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:35 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 735,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001535289-26-000003 · ownership.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,000 Underlying: Common Stock · 735,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 22:44 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 4,650 | $2.21 | $10,288.13 |
DisclosureSEC source: 0000950170-25-048775 · ownership.xml · nonDerivative · entry 2 Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Child #1 Disclosed balance after: 4,650 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.2450, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 22:44 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 22,026 | $2.24 | $49,384.49 |
DisclosureSEC source: 0000950170-25-048775 · ownership.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,383 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote. F2 · balance_after: Previous Form 4s filed on behalf of the Reporting Person under-reported the Reporting Person's holdings by 1,100 shares of Common Stock. The amount reported in this Form 4 reflects the correct amount. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:27 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 650,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000950170-25-033662 · ownership.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-03-03 F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| December 04, 2024 Filed Dec 4, 2024 22:20 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 8,000 | $3.77 | $30,132.00 |
DisclosureSEC source: 0000950170-24-133355 · ownership.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,257 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7596 to $3.7700, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 6,600 | $3.80 | $25,080.00 |
DisclosureSEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 3 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA of Spouse Disclosed balance after: 66,600 Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 5,400 | $3.80 | $20,520.00 |
DisclosureSEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 2 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA of Reporting Owner Disclosed balance after: 5,400 Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 14,500 | $3.78 | $54,868.00 |
DisclosureSEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,072 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.645 to $3.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:09 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0000950170-24-076716 · ownership.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 21:19 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 100,000 | $1.17 | $117,430.00 |
DisclosureSEC source: 0000950170-24-073145 · ownership.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,572 F1 · price: The price in column 4 is a weighted average price. The prices actually paid ranged from $1.1650 to $1.1800. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or a securityholder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:42 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 3,338,878 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-23-034479 · rdgdoc.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,793,635 Underlying: Common Stock · 3,338,878 shares Expires 2033-12-12 F1 · derivative.exercise_date: 25% vested as of 12/12/2023, and the remaining 75% will vest over the next three (3) years, commencing on 12/12/2024, until fully vested. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 23:46 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 80,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001415889-20-000964 · form4-04072020_040436.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-04-06 F2 · price: Options issued in connection with the Reporting Person's service on the Issuer's Board of Directors. F1 · derivative.exercise_date: 25% of the options vest immediately, with the remainder vesting in equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 23:47 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | PurchaseCommon Stock | 38,583 | $1.30 | $49,968.84 |
DisclosureSEC source: 0001415889-19-000017 · form4-01022019_030137.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,617 Read SEC document |
| July 12, 2018 Filed Jul 17, 2018 01:08 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001121 · form4-07162018_060717.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,034 F1 · price: Represents grant of restricted stock. Shares shall vest in increments as follows: (i) 1/6 upon the acceptance of a U.S. IND for MS 1819; (ii) 1/6 upon the the first CF patient dosed with MS1819 anywhere in the globe; (iii) 1/6 upon upon enrollment of the first 30 patients in a CF trial; (iv) 1/6 on July 12, 2019; (v) 1/6 on July 12, 2020; and (vi) 1/6 on July 12, 2021. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:20 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | OtherOptions · Derivative | 100,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-17-001785 · form4-11142017_031107.xml · derivative · entry 3 Spoor Johan M. · CIK 0001535289 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2021-01-04 F2 · security: Represents options granted to the Reporting Person by third parties. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:20 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | OtherCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001415889-17-001785 · form4-11142017_031107.xml · nonDerivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,034 Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:36 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 100,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001415889-17-000210 · form4-02072017_010228.xml · derivative · entry 1 Spoor Johan M. · CIK 0001535289 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.